F. Ducimetiere, A. Lurkin, and D. Ranchere-vince, Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing, PLoS One, vol.6, p.20294, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00799650

, Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.102-112, 2014.

A. Italiano, S. Mathoulin-pelissier, L. Cesne, and A. , Trends in survival for patients with metastatic soft-tissue sarcoma, Cancer, vol.117, pp.1049-1054, 2011.

X. Garcia-del-muro, A. Lopez-pousa, and J. Maurel, Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study, J Clin Oncol, vol.29, pp.2528-2533, 2011.

O. Mir, T. Brodowicz, and A. Italiano, Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, vol.17, pp.1732-1742, 2016.

P. Reichardt, M. Leahy, G. D. Muro, and X. , Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study, Sarcoma, p.740279, 2012.

C. Coens, W. T. Vand-der-graaf, and J. Y. Blay, Health-related quality-of-life results from PALETTE : a randomized, doubleblind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease progressed during or after prior chemotherapy-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Global Network study (EORTC 62072), Cancer, vol.121, pp.2933-2941, 2015.

N. J. Gough, C. Smith, J. R. Ross, J. Riley, and J. I. , Symptom burden, survival and palliative care in advanced soft tissue sarcoma, Sarcoma, p.325189, 2011.

S. Patil, R. A. Figlin, and T. E. Hutson, Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-a, Br J Cancer, vol.106, pp.1587-1590, 2012.

J. L. Beaumont, J. M. Salsman, and J. Diaz, Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma, Cancer, vol.122, pp.1108-1115, 2016.

W. T. Van-der-graaf, J. Y. Blay, and S. P. Chawla, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind placebo-controlled phase 3 trial, Lancet, vol.379, pp.1879-1886, 2012.

J. F. Guest, E. Sladkevicius, N. Gough, M. Linch, and R. Grimer, Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom, Sarcoma, p.863056, 2013.

S. L. Shingler, P. Swinburn, and A. Lloyd, Elicitation of health state utilities in soft tissue sarcoma, Qual Life Res, vol.22, pp.1697-1706, 2013.